SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending amidst a sell-off, driven by concerns over unfavorable sports outcomes impacting profits, potential state-level tax headwinds, and the rise of prediction markets. The community is debating the impact of these factors and whether the stock is oversold ahead of earnings, with some viewing the dip as a buying opportunity while others express concern over the company's future prospects. Discussions also include comparisons to competitors and speculation about potential buyouts or strategic shifts.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

$RAGE is trending as the community rallies behind this OG meme coin, emphasizing its roots in internet culture. Discussions highlight the power of a united community and the return to authentic meme-driven projects. The focus is on long-term conviction and building a strong, dedicated following.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI is trending as the community rallies around the token with a strong sense of conviction and positive sentiment, reflected in the "We're All Gonna Make It" (WAGMI) mantra. Discussions also involve potential pumps, dips, and the ongoing battle with bears, while some traders are watching tickers like $SOL, $HERMETO, and others as potential plays.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius Holdings is trending due to mixed reactions following earnings, with discussions focusing on the company's growth, acquisition impacts, and potential manipulation; the community is debating whether the dip presents a buying opportunity or reflects deeper concerns around profitability and accounting. Optimistic investors highlight revenue growth, market share, and the PepsiCo partnership, while others express concern over P/E ratio and one-time charges.

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

SNAP is trending following news of an AI partnership with Perplexity, sending the stock upward. Community chatter highlights the potential for increased user engagement and monetization through AI integration, while some express skepticism. Bullish sentiment is building, with some seeing this as a major turnaround catalyst, while others remain cautious.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending as investors discuss the potential catalysts from the upcoming earnings call, including updates on partnerships and the overall financial outlook. Community members are debating the likelihood of a partnership announcement, particularly for the CIC (Combination Influenza/COVID) vaccine, and expressing concerns about the company's performance and leadership. Some traders are also monitoring short interest, speculating about a potential squeeze.

Duolingo, Inc. is a language-learning website and mobile application, which engages in the development of a free language learning website and crowd sourced text translation platform. It offers Duolingo for Schools, a free, web-based tool that aims to make it easier for teachers to use the Duolingo platform in a structured learning environment, and English Test, an online, on-demand assessment of English proficiency. The company was founded by Luis von Ahn and Severin Hacker in 2011 and is headquartered in Pittsburgh, PA.

Duolingo Inc - Ordinary Shares - Class A

Duolingo Inc

Duolingo ($DUOL) is trending as investors discuss whether its recent dip presents a buying opportunity, despite some analysts lowering price targets; the community is debating the company's growth prospects and its ability to compete with AI-powered language tools, while also noting that Duolingo's chess feature and potential as a broader AI learning platform are positives.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is trending amid speculation of a potential buyout or significant partnership, fueled by a report from STAT News, with community members weighing the possibilities and potential valuation. Discussions also revolve around earnings, pipeline progress, and the company's prospects beyond COVID-19 vaccines, with some noting a boost from a recent study suggesting their mRNA vaccines could enhance cancer immunotherapy.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is trending due to strong earnings reports, highlighting a 40% year-over-year increase in total product revenue and its first-ever profitable EPS. Community discussions revolve around the impressive growth of Recorlev, positive revenue guidance, and speculation about potential acquisitions. The overall sentiment is bullish, with many anticipating continued growth and profitability for the company.

Internet Computer (IC) is the world’s first blockchain that is capable of running at web speed at unrestrictive capacities. Built by the DFINITY Foundation, IC aims to recreate the web by supporting smart contract development at scale and changing the way people can interact using web services. Internet Computer aims to extend the public internet, so that it can be the world’s computing platform, in a decentralized manner. Internet Computer sets to revolutionalize the design of the crypto economy, with an aim to overhaul traditional software services.   The project was founded in October 2016 by Dominic WIllams and have raised a total of $121 million from investors such as Adreessen Horowitz, Polychain Capital, Multicoin Capital and such. On May 10, 2021, DFINITY launched the Internet Computer into the public domain, marking it a major milestone for ICP as it means the internet now functions as a decentralised global computer. This is marked by the release of all of the Internet Computer’s source code into the public domain, as well as ICP utility token that allows tens of thousands of community members to govern the Internet Computer network.  ICP is Internet Computer's native token. It plays three prominent roles:  1. Network Governance: Users that participate in the governance will be rewarded with ICPI 2. Production of Cycles for Compute: ICP can be converted into cycles where it is used as the transaction fee to access the network. Cycles are burned after used. 3. Rewarding Users: ICP is used as the rewards to incentivize users to participate in the network such as securing the network.

Internet Computer

Internet Computer (ICP) is trending as community members celebrate recent gains, with some eyeing a run toward previous highs and speculating it could outperform competitors like Solana. Fueling the excitement are discussions around potential institutional adoption and its technology which is described as revolutionary, including its AI integration. The community is closely watching resistance levels, anticipating a breakout.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Dynavax Technologies (DVAX) Surpasses Q3 Earnings Estimates

Dynavax Technologies (DVAX) delivered earnings and revenue surprises of +50.00% and -0.23%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Qiagen (QGEN) Q3 Earnings and Revenues Surpass Estimates

Qiagen (QGEN) delivered earnings and revenue surprises of +5.17% and +1.25%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Nuvation Bio Inc. (NUVB) Reports Q3 Loss, Tops Revenue Estimates

Nuvation Bio (NUVB) delivered earnings and revenue surprises of +5.88% and +95.53%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Dynavax to Report Third Quarter 2025 Financial Results and Host Conference Call on November 5, 2025

Dynavax to Report Third Quarter 2025 Financial Results and Host Conference Call on November 5, 2025 Dynavax to Report Third Quarter 2025 Financial Results and Host Conference Call on November 5, 2025...

Dynavax Presents Positive Topline Data from Part 1 of Phase 1/2 Trial for Shingles Vaccine Candidate at IDWeek 2025 and Announces Initiation of Part 2 of Trial

Dynavax Presents Positive Topline Data from Part 1 of Phase 1/2 Trial for Shingles Vaccine Candidate at IDWeek 2025 and Announces Initiation of Part 2 of Trial Dynavax Presents Positive Topline Data...

Amgen (AMGN) Moves 3.5% Higher: Will This Strength Last?

Amgen (AMGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Dynavax Technologies Corp. (DVAX) on Thursday said that its experimental Shingles vaccine yielded positive results in an early-to-mid-stage study as compared to GSK Plc’s (GSK) Shingrix vaccine. &nbsp;Herpes zoster, or shingles, is a viral infection that affects approximately one in three people in their lifetime. The disease is characterized by a painful rash and can lead to serious complications, particularly in older adults.The company evaluated the experimental vaccine in participants aged 50 to 69 years for the first part of the study, and it showed that at one month after the second vaccine dose, Z-1018 <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.dynavax.com/news-releases/news-release-details/dynavax-announces-positive-topline-phase-12-results-supporting">demonstrated</a> immune responses similar to those observed in the arm receiving Shingrix with a favorable tolerability profile.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/DVAX">DVAX stock</a> jumped from ‘bearish’ to ‘bullish’ over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels. Shares of the company traded 6% higher on Thursday afternoon at the time of writing.<figure class="image"><img style="aspect-ratio:569/59;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_21_at_2_08_19_PM_png_e38a9696ce.webp" alt="DVAX's Sentiment Meter and Message Volume as of 2:10 p.m. ET on Aug. 21, 2025 | Source: Stocktwits" width="569" height="59"><figcaption>DVAX's Sentiment Meter and Message Volume as of 2:10 p.m. ET on Aug. 21, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user suggested holding the stock patiently.<stembedurl>https://stocktwits.com/poorguy/message/626078462</stembedurl>The company said that it now intends to advance Z-1018 into the next part of the study in adults 70 years of age and older in the second half of the year. At the dose formulation and regimen chosen for advancing to the next part of the trial, Z-1018 achieved 100% antibody production compared to Shingrix at 96.9%, the company said.Furthermore, only 12.5% of participants receiving Z-1018 at the dose reported local post-injection reactions, compared to 52.6% for Shingrix, the company said. It also noted that 27.5% participants reported body-wide reactions with the experimental vaccine, compared to 63.2% in Shingrix."These positive data mark an important inflection point for our novel shingles vaccine program as we strive to develop a product with a potential best-in-class profile with the aim to disrupt the multi-billion-dollar shingles vaccine market, which is currently dominated by one product," said CEO Ryan Spencer, referring to Shingrix.DVAX stock is down by 14% this year and by about 3% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/nio-unveils-new-es8-starting-at-rmb-416800/chsj2ghRdiq">Nio Stock Rocketed 10% Today And Retail Believes It Could Hit The $10-Mark By Earnings – Find Out More</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Medical syringe is seen with Dynavax company logo displayed on a screen in the background in this illustration photo taken in Poland on June 16, 2020. (Photo Illustration by Jakub Porzycki/NurPhoto via Getty Images)

Dynavax’s Experimental Shingles Vaccine Shows Positive Results In Study: Retail Expects Stock Rally To Continue Into Friday

The company said that it now intends to advance Z-1018 into the next part of the study in adults 70 years of age and older in the second half of the year.

Equity

The company said that it now intends to advance Z-1018 into the next part of the study in adults 70 years of age and older in the second half of the year.


Dynavax Technologies (DVAX) Q2 Earnings and Revenues Beat Estimates

Dynavax Technologies (DVAX) delivered earnings and revenue surprises of +16.67% and +8.99%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Protagonist Therapeutics (PTGX) Reports Q2 Loss, Lags Revenue Estimates

Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of -3.77% and -46.67%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Exelixis (EXEL) Beats Q2 Earnings Estimates

Exelixis (EXEL) delivered earnings and revenue surprises of +15.38% and -1.84%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Current Price	$10.30
Prev Close	$10.05
Open	$9.95
Dividend Yield	0.00%
50-Day Moving Average	$9.99
Beta	0.71
Avg. Volume	1.26M
PE Ratio	-21.70

52-Week High	$14.63
52-Week Low	$9.20
Market Capitalization	$1.21B
EPS (Annual)	$0.2048
Price to Book	2.44
Revenue Per Employee	$684,558.03
Enterprise Value/EBITDA	N/A

DVAX
Dynavax Technologies Corp.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest DVAX News

DVAXDynavax Technologies Corp.